Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor

BMC Neuroscience

Suresh Sundram¹  Anthony Sugiharto-Winarno³  Peter Malcolm³  Betty Zhang³  Avril Pereira² 

[1] Northern Psychiatry Research Centre, The Northern Hospital, Cooper Street, Epping, VIC 3076, Australia;Centre for Neuroscience, The University of Melbourne, Parkville, VIC 3010, Australia;Department of Molecular Psychopharmacology, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Kenneth Myer Building, At Genetics Lane on Royal Parade, Parkville, VIC 3010, Australia

关键词: Schizophrenia;    c-Fos;    p90RSK;    ERK;    Signaling;    Antipsychotic drugs;   

Others  :  1092382
DOI  :  10.1186/1471-2202-15-30

 received in 2014-02-03, accepted in 2014-02-14,  发布年份 2014

【 摘 要 】

Background

Signaling pathways outside dopamine D2 receptor antagonism may govern the variable clinical profile of antipsychotic drugs (APD) in schizophrenia. One postulated mechanism causal to APD action may regulate synaptic plasticity and neuronal connectivity via the extracellular signal-regulated kinase (ERK) cascade that links G-protein coupled receptors (GPCR) and ErbB growth factor signaling, systems disturbed in schizophrenia. This was based upon our finding that the low D2 receptor affinity APD clozapine induced initial down-regulation and delayed epidermal growth factor receptor (EGFR or ErbB1) mediated activation of the cortical and striatal ERK response in vivo distinct from olanzapine or haloperidol. Here we map whether the second generation atypical APDs aripiprazole and quetiapine affect the EGFR-ERK pathway and its substrates p90RSK and c-Fos in mouse brain, given their divergent agonist and antagonist properties on dopaminergic transmission, respectively.

Results

In prefrontal cortex, aripiprazole triggered triphasic ERK phosphorylation that was EGFR-independent but had no significant effect in striatum. Conversely quetiapine did not alter cortical ERK signaling but elevated striatal ERK levels in an EGFR-dependent manner. Induction of ERK by aripiprazole did not affect p90RSK signaling but quetiapine decreased RSK phosphorylation within 1-hour of administration. The transcription factor c-Fos by comparison was a direct target of ERK phosphorylation induced by aripiprazole in cortex and quetiapine in striatum with protein levels in temporal alignment with that of ERK.

Conclusions

These data indicate that aripiprazole and quetiapine signal to specific nuclear targets of ERK, which for quetiapine occurs via an EGFR-linked mechanism, possibly indicating involvement of this system in its action.

【 授权许可】

   
2014 Pereira et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Pereira A, Fink G, Sundram S: Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor. J Mol Neurosci 2009, 39(1–2):185-198.
• [2]Pereira A, Sugiharto-Winarno A, Zhang B, Malcolm P, Fink G, Sundram S: Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs. Int J Neuropsychopharmacol 2012, 15(8):1149-1160.
• [3]Pereira A, Zhang B, Malcolm P, Sundram S: Clozapine regulation of p90RSK and c-Fos signaling via the ErbB1-ERK pathway is distinct from olanzapine and haloperidol in mouse cortex and striatum. Progr Neuro Psychopharmacol Biol Psychiatr 2013, 40:353-363.
• [4]Engel SR, Creson TK, Hao Y, Shen Y, Maeng S, Nekrasova T, Landreth GE, Manji HK, Chen G: The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement. Mol Psychiatry 2009, 14(4):448-461.
• [5]Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10(1):40-68. image 45
• [6]Thomas GM, Huganir RL: MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 2004, 5(3):173-183.
• [7]Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Therapeut 2002, 302(1):381-389.
• [8]Nemeroff CB, Kinkead B, Goldstein J: Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatr 2002, 63(Suppl 13):5-11.
• [9]Ishii D, Matsuzawa D, Kanahara N, Matsuda S, Sutoh C, Ohtsuka H, Nakazawa K, Kohno M, Hashimoto K, Iyo M, et al.: Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway. Neurosci Lett 2010, 471(1):53-57.
• [10]Bruins Slot LA, De Vries L, Newman-Tancredi A, Cussac D: Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 2006, 534(1–3):63-70.
• [11]Bruins Slot LA, Palmier C, Tardif S, Cussac D: Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation. Neuropharmacology 2007, 53(2):232-241.
• [12]Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al.: Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Therapeut 2007, 320(1):1-13.
• [13]Ishima T, Iyo M, Hashimoto K: Neurite outgrowth mediated by the heat shock protein Hsp90alpha: a novel target for the antipsychotic drug aripiprazole. Translational Psychiatry 2012, 2:e170.
• [14]Lu XH, Dwyer DS: Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J Mol Neurosci 2005, 27(1):43-64.
• [15]Di Benedetto B, Kuhn R, Nothdurfter C, Rein T, Wurst W, Rupprecht R: N-desalkylquetiapine activates ERK1/2 to induce GDNF release in C6 glioma cells: a putative cellular mechanism for quetiapine as antidepressant. Neuropharmacology 2012, 62(1):209-216.
• [16]Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, Li X, Dyck LE, Devon RM, Deng Y, et al.: Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 2008, 13(7):697-708.
• [17]Tomasetti C, Dell’Aversano C, Iasevoli F, Marmo F, de Bartolomeis A: The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Progr Neuro Psychopharmacol Biol Psychiatr 2011, 35(1):184-197.
• [18]Xing J, Ginty DD, Greenberg ME: Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996, 273(5277):959-963.
• [19]Sgambato V, Pages C, Rogard M, Besson MJ, Caboche J: Extracellular signal-regulated kinase (ERK) controls immediate early gene induction on corticostriatal stimulation. J Neurosci 1998, 18(21):8814-8825.
• [20]Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S: Partial agonists in schizophrenia–why some work and others do not: insights from preclinical animal models. Int J Neuropsychopharmacol 2011, 14(9):1165-1178.
• [21]Vahid-Ansari F, Nakabeppu Y, Robertson GS: Contrasting effects of chronic clozapine, Seroquel(TM) (ICI 204,636) and haloperidol administration of deltaFosB-like immunoreactivity in the rodent forebrain. Eur J Neurosci 1996, 8(5):927-936.
• [22]Oka T, Hamamura T, Lee Y, Miyata S, Habara T, Endo S, Taoka H, Kuroda S: Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. Life Sci 2004, 76(2):225-237.
• [23]Stefan M, Travis M, Murray RM: An Atlas of Schizophrenia. London: The Parthenon Publishing Group; 2002.
• [24]Bowles TM, Levin GM: Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 2003, 37(5):687-694.
• [25]Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003, 60(7):681-690.
• [26]Urban JD, Vargas GA, von Zastrow M, Mailman RB: Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007, 32(1):67-77.
• [27]Zocchi A, Fabbri D, Heidbreder CA: Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 2005, 387(3):157-161.
• [28]Ghaemi SN, Ko JY: Quetiapine-related tardive dyskinesia. Am J Psychiatry 2001, 158(10):1737.
• [29]Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatr 2002, 47(1):27-38.
• [30]Kapur S, Seeman P: Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001, 158(3):360-369.
• [31]Sumner BE, Cruise LA, Slattery DA, Hill DR, Shahid M, Henry B: Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology 2004, 171(3):306-321.
• [32]Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, Gunnarsdottir S, Walker N, Petursson H, Crombie C, et al.: Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 2003, 72(1):83-87.
• [33]Hanninen K, Katila H, Anttila S, Rontu R, Maaskola J, Hurme M, Lehtimaki T: Epidermal growth factor a61g polymorphism is associated with the age of onset of schizophrenia in male patients. J Psychiatr Res 2007, 41(1–2):8-14.
• [34]Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, Tsuchiya K, Someya T, Kakita A, Takahashi H, Nawa H: Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry 2002, 7(7):673-682.
• [35]Futamura T, Kakita A, Tohmi M, Sotoyama H, Takahashi H, Nawa H: Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: implication for epidermal growth factor in cognitive development. Mol Psychiatry 2003, 8(1):19-29.
• [36]Wong RW, Guillaud L: The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine Growth Factor Rev 2004, 15(2–3):147-156.
• [37]Bespalov A, Jongen-Relo AL, van Gaalen M, Harich S, Schoemaker H, Gross G: Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. J Pharmacol Exp Therapeut 2007, 320(2):944-950.
• [38]Yan B, He J, Xu H, Zhang Y, Bi X, Thakur S, Gendron A, Kong J, Li XM: Quetiapine attenuates the depressive and anxiolytic-like behavioural changes induced by global cerebral ischemia in mice. Behav Brain Res 2007, 182(1):36-41.
• [39]Ellis AG, Doherty MM, Walker F, Weinstock J, Nerrie M, Vitali A, Murphy R, Johns TG, Scott AM, Levitzki A, et al.: Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol 2006, 71(10):1422-1434.